Aldevron has expanded its leadership team by appointing Mike Busch as Vice President of Human Resources.
Aldevron and Odylia, a nonprofit organization working to develop treatments for ultra-rare ocular diseases using gene therapy, have entered into an agreement in which Aldevron is a member of Odylia.
Don Kania, Ph.D., has been appointed to the Board of Directors of Aldevron. Dr. Kania joins Michael Chambers, CEO of Aldevron; and Ethan K. Liebermann and Mark H. Carter, both from TA Associates, on the board.
Aldevron, Sanford Health, North Dakota State University highlight advances in rare disease treatment
Area organizations Aldevron, Sanford Health, and North Dakota State University (NDSU) have joined forces to bring together a special event titled, "From the Valley to the Mountain: The RARE Impact of the Red River Valley," on Wednesday, April 11 from 5:30-8 p.m. at Aldevron corporate headquarters, 4837 Amber Valley Parkway, Fargo N.D. The evening will start with refreshments, a Meet and Greet, and a silent auction, followed by leaders in science and medicine from the Red River Valley sharing their contributions toward advancing gene therapy and rare disease research efforts around the world.
Aldevron has selected AES Clean Technology, a leader in the design, manufacturing, and construction of modular cleanroom systems, to design modular cleanrooms for Aldevron’s $30 million, 70,000 square-foot manufacturing facility in Fargo, N.D. Cleanroom construction is underway with target completion date of early summer.
New plasmid to reduce cost and timeline for gene therapy manufacturing
Aldevron, the world’s leading contract plasmid manufacturing organization, has announced the immediate availability of an off-the-shelf version of pXX6-80, a common adeno-associated virus (AAV) helper plasmid. The plasmid is designed to reduce the cost of AAV manufacturing and subsequent gene therapy applications, while helping Aldevron’s clients meet regulatory requirements.